|
Jan 2
|
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
|
|
Dec 22
|
Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable?
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 18
|
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 34% Share Price Surge Not Quite Adding Up
|
|
Dec 8
|
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
|
|
Dec 7
|
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
|
|
Jul 9
|
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
|